 |
| Amatuxinab is granted orphan drug status. |
OncLive.com reports that the Food and Drug Administration had granted orphan drug status to Amatuximab,
which is used to treat patients diagnosed with malignant pleural mesothelioma,
the most common form of mesothelioma. Amatuximab (MORAb-009) is a monoclonal
antibody which targets mesothelin, a cell surface glycoprotein linked to cell
adhesion is manifested on specific types of cancer, including mesothelioma cancer, as
well as pancreatic ductal adenocarcinoma, epithelial ovarian cancer, and lung
adenocarcinoma.
No comments:
Post a Comment